Eli Lilly signed a deal with Profluent worth up to $2.25 billion on April 28, giving the pharmaceutical giant exclusive rights to new medicines developed using Profluent’s AI-driven DNA and protein editing technology, the latest in a string of multibillion-dollar AI drug discovery partnerships Lilly has pursued over the past year as it races to build out a differentiated pipeline.
What Profluent’s Technology Does
Profluent uses generative AI models trained on massive genomic datasets to design novel gene-editing proteins and therapeutic DNA sequences, an approach the company argues can create more precise and effective editing tools than those discovered through traditional protein engineering methods. The technology builds on the broader wave of AI applications in genomics that has accelerated following breakthroughs in protein structure prediction models in recent years.
Lilly’s Pattern of AI Partnerships
The Profluent deal follows Lilly’s earlier agreement with Insilico Medicine worth up to $2.75 billion, signed in March, and its longer-standing partnership with Nvidia to build a dedicated AI supercomputer for drug discovery, together representing a comprehensive strategy of securing access to multiple distinct AI drug discovery approaches rather than betting on a single technology platform. Lilly has emerged as one of the most aggressive pharmaceutical companies in pursuing AI partnerships across different modalities.
Why DNA Editing Represents a Distinct Opportunity
Gene and DNA editing therapies represent a therapeutic category with enormous potential but historically high technical difficulty, since editing tools need extreme precision to avoid unintended genomic changes that could cause serious side effects, a challenge AI-driven design approaches are specifically aimed at addressing by better predicting how editing proteins will interact with target DNA sequences. Success in this area could open treatment possibilities for genetic diseases that have previously lacked viable therapeutic approaches.
Deal Structure and Financial Terms
Lilly’s $2.25 billion deal with Profluent is structured with an upfront payment and a series of milestone payments tied to specific development achievements, a common structure across AI pharma partnerships that limits Lilly’s near-term financial exposure while giving Profluent meaningful capital to fund continued platform development. Lilly retains exclusive rights to any resulting medicines, meaning Profluent’s commercial upside depends entirely on the success of this single pharma relationship for products developed under the agreement.
Industry Context and Skepticism
The deal adds to broader industry questions about whether the current wave of AI drug discovery investment, now totaling tens of billions of dollars in potential payments across dozens of deals, will translate into a meaningfully faster pipeline of approved medicines, given that the industry has yet to bring an AI-substantially-designed drug to market. Lilly executives have defended the pace of dealmaking as a necessary bet given the long lead times required for any drug discovery approach to prove itself.
What’s Next
Profluent and Lilly are expected to begin identifying specific disease targets for the DNA-editing collaboration in the coming months, with any resulting candidates likely years away from entering human clinical trials given the additional safety testing required for gene-editing therapeutics specifically. The partnership’s progress will be an important signal of how AI-driven gene editing tools perform relative to established, non-AI gene editing platforms already in clinical development industry-wide.
Photo: AlexAntropov86 / PIXABAY via Pixabay
